C4 Therapeutics’ $209.76 Million IPO


Goodwin Procter LLP advised C4 Therapeutics on the deal.

C4 Therapeutics, Inc. (Nasdaq: CCCC) announced its upsized initial public offering for gross proceeds of $209.76 million, before deducting underwriting discounts and commissions and other offering expenses. The company sold 11,040,000 shares of its common stock, including shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $19.00 per share. The transaction closed on October 6, 2020.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

The bi-coastal Goodwin deal team was led by Lawrence Wittenberg (Picture), Edwin O’Connor and Shoaib Ghias, and included Steven LoCascio, Rob Intile, Jr., Tracey Parker, Julie Tibbets, Kristina Jacobs, Roger A. Cohen, Madison Marcus, Sarah Bock, L. Morgan Frisoli, Daniel Karelitz, Leon Peschel, Ian Longacre, Eugene Shin, Tim Holahan, James Matarese, Richard Kline and Nathan Needle.

Involved fees earner: Sarah Bock – Goodwin Procter; Roger Cohen – Goodwin Procter; Morgan Frisoli – Goodwin Procter; Shoaib Ghias – Goodwin Procter; Timothy Holahan – Goodwin Procter; Rob Intile Jr – Goodwin Procter; Kristina Jacobs – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Richard Kline – Goodwin Procter; Steven LoCascio – Goodwin Procter; Ian Longacre – Goodwin Procter; Madison Marcus – Goodwin Procter; James Matarese – Goodwin Procter; Edwin O’Connor – Goodwin Procter; Tracey Parker – Goodwin Procter; Leon Peschel – Goodwin Procter; Eugene Shin – Goodwin Procter; Julie Tibbets – Goodwin Procter; Lawrence Wittenberg – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: C4 Therapeutics, Inc.;

Author: Ambrogio Visconti